Sy-12321
Preclinical
Sy-12321 is one of 2 therapeutic programs targeting ALK Positive Malignancies. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
1 competitor in ALK Positive Malignancies
#DrugCompanyPhaseTrials
1Zykadia
NovartisApproved
Sy-12321
SShouyao Holdings (Beijing) Co. LTD
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
ALK Positive Malignancies1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Sy-12321. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]